Transcranial Direct Current Stimulation for Peripheral Neuropathy

This trial tests a non-invasive brain stimulation technique called transcranial direct current stimulation (tDCS) to determine its effectiveness in reducing symptoms of chemotherapy-induced peripheral neuropathy (CIPN) in cancer survivors. CIPN can lead to numbness, tingling, pain, and movement issues following chemotherapy. The trial includes two groups: one receives active tDCS, and the other receives a placebo version before switching. Cancer survivors who experience numbness or pain after chemotherapy and can walk unaided might find this trial suitable. As an unphased trial, it offers a unique opportunity to explore innovative treatments that could enhance the quality of life for cancer survivors.

Research has shown that transcranial direct current stimulation (tDCS) is generally safe for people. In past studies, tDCS did not cause any serious side effects. Participants most commonly reported minor side effects such as itching, tingling, headaches, and a burning sensation, all of which were temporary and not severe.

When used according to guidelines, studies have found tDCS to be well-tolerated. This non-invasive brain stimulation has been tested for various pain conditions and maintains a good safety record. Although the FDA has not specifically approved tDCS for treating peripheral neuropathy, it has been used safely for other types of nerve pain.

Unlike standard treatments for peripheral neuropathy, which often include medications like gabapentin or pregabalin that focus on symptom relief, transcranial direct current stimulation (tDCS) offers a non-invasive approach that targets the brain directly. tDCS uses a low electrical current applied to the scalp to stimulate the sensorimotor cortex, potentially altering pain perception and providing relief. Researchers are excited about tDCS because it has the potential to offer a drug-free alternative with fewer side effects, and it may provide quicker symptom relief compared to traditional medications.

This trial will compare the effects of active transcranial direct current stimulation (tDCS) with sham tDCS for peripheral neuropathy. Research has shown that tDCS can reduce pain in individuals with nerve-related pain conditions. In one study, participants experienced less pain after just three sessions of tDCS. Another study found that tDCS provided short-term relief for those with chronic nerve pain. This gentle brain stimulation method has also helped manage pain in conditions like fibromyalgia and migraines. Overall, tDCS appears promising in reducing pain and improving symptoms related to nerve issues.¹²³⁴⁶